Trade

with

Regulus Therapeutics Inc
(NASDAQ: RGLS)
AdChoices
17.33
+2.79
+19.19%
After Hours :
17.35
+0.02
+0.12%

Open

14.40

Previous Close

14.54

Volume (Avg)

5.53M (672.20k)

Day's Range

14.10-18.07

52Wk Range

5.40-18.07

Market Cap.

751.99M

Dividend Rate ( Yield )

-

Beta

-

Shares Outstanding

43.39M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 19.57M

    • Net Income

    • -18.67M

    • Market Cap.

    • 751.99M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -206.65

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • -

    • Forward P/E

    • -17.70

    • Price/Sales

    • 52.36

    • Price/Book Value

    • 9.16

    • Price/Cash flow

    • -8.45

      • EBITDA

      • -17.30M

      • Return on Capital %

      • -27.91

      • Return on Equity %

      • -43.84

      • Return on Assets %

      • -27.91

      • Book Value/Share

      • 1.89

      • Shares Outstanding

      • 43.39M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 19.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.97

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -84.50

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -206.82

            • 39.38

            • Net Profit Margin

            • -206.65

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.15

              • 0.76

              • Current Ratio

              • 9.58

              • 2.92

              • Quick Ratio

              • 9.19

              • 2.35

              • Interest Coverage

              • -738.18

              • 38.02

              • Leverage Ratio

              • 1.39

              • 2.21

              • Book Value/Share

              • 1.89

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -9.62

                • 217.39

                • P/E Ratio 5-Year High

                • -18.81

                • 634.30

                • P/E Ratio 5-Year Low

                • -5.87

                • 124.82

                • Price/Sales Ratio

                • 19.88

                • 9.52

                • Price/Book Value

                • 3.48

                • 8.61

                • Price/Cash Flow Ratio

                • -8.45

                • 50.51

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -43.84

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -27.91

                    (-)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -36.31

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.14

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -17.80M
                  Operating Margin
                  -90.97
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -8.45
                  Ownership

                  Institutional Ownership

                  94.60%

                  Top 10 Institutions

                  85.36%

                  Mutual Fund Ownership

                  25.62%

                  Float

                  28.29%

                  5% / Insider Ownership

                  0.19%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Growth Company Fund

                  •  

                    2,930,181

                  • 0.00

                  • 6.75

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    1,746,479

                  • 13.62

                  • 4.02

                  • Fidelity® Series Growth Company Fund

                  •  

                    703,400

                  • 0.00

                  • 1.62

                  • Goldman Sachs Small/Mid Cap Growth Fund

                  •  

                    701,703

                  • -3.38

                  • 1.62

                  • iShares Nasdaq Biotechnology

                  •  

                    561,348

                  • -0.47

                  • 2.75

                  • Fidelity Advisor® Growth Opportunities

                  •  

                    337,200

                  • 0.00

                  • 0.78

                  • T. Rowe Price New America Growth Fund

                  •  

                    322,900

                  • 0.00

                  • 0.74

                  • Prudential Jennison Health Sciences

                  •  

                    319,659

                  • 0.00

                  • 0.74

                  • Vanguard Total Stock Mkt Idx

                  •  

                    287,819

                  • 0.00

                  • 0.66

                  • Fidelity Advisor® Biotechnology Fund

                  •  

                    225,391

                  • 21.43

                  • 0.52

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Isis Pharmaceuticals Inc

                  •  

                    7,049,500

                  • 0.00%

                  • 16.33

                  • Fidelity Management and Research Company

                  •  

                    6,317,134

                  • +0.04%

                  • 14.56

                  • Alnylam Pharmaceuticals Inc

                  •  

                    6,150,500

                  • 0.00%

                  • 14.25

                  • Sanofi

                  •  

                    5,053,779

                  • +34.77%

                  • 11.71

                  • GlaxoSmithKline PLC

                  •  

                    1,947,037

                  • -41.51%

                  • 4.51

                  • Healthcor Management, L.p.

                  •  

                    1,550,000

                  • -1.59%

                  • 3.57

                  • Wellington Management Company, LLP

                  •  

                    940,070

                  • +26.19%

                  • 2.17

                  • BlackRock Fund Advisors

                  •  

                    849,286

                  • +4.05%

                  • 1.96

                  • Goldman Sachs Asset Management, L.P.

                  •  

                    791,207

                  • +0.87%

                  • 1.82

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Speculative Growth

                  Style

                  -

                  Regulus Therapeutics Inc is a biopharmaceutical company. The Company is engaged in discovering & developing drugs that target micro RNAs to treat a range of diseases.

                  Key People

                  Dr. Kleanthis G. Xanthopoulos,PhD

                  CEO/Director/President

                  Dr. Stelios Papadopoulos,PhD

                  Chairman of the Board/Director

                  Ms. B. Lynne Parshall, J.D.

                  Director

                  Dr. Bruce L.A. Carter,PhD

                  Director

                  Dr. Douglas E. Williams,PhD

                  Director

                  • Regulus Therapeutics Inc

                  • 3545 John Hopkins Court

                  • San Diego, CA 92121

                  • USA.Map

                  • Phone: +1 858 202-6300

                  • Fax: -

                  • regulusrx.com

                  Incorporated

                  2007

                  Employees

                  76

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: